Remigromig met the non-inferiority endpoint vs ranibizumab in the BRUNELLO DME trial, but PDR adverse events were higher.

Weltruza is the second US-approved product from Israel-based Teva's partnership with French ⁠biotech company Medincell after Uzedy, a long-acting injectable form of antipsychotic drug risperidone, ...

Merck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led ...

PDR-related adverse events and treatment discontinuations were more frequent with remigromig, warranting further safety evaluation Remigromig targets the Wnt pathway, offering a potential alternative ...

Merck ( MRK) said its experimental eye drug remigromig improved vision in patients with a diabetes-related eye disease, ...

Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at one year in patients with diabetic macular ...

This article is intended for physicians and medical professionals.Who should read this article Ophthalmologists treating PCV ...

A UN report says more than 251 tonnes of medical products were seized across Central Africa between 2020 and 2025, exposing a lucrative illicit trade that.

Australians living with wet age-related macular degeneration may soon be able to replace regular eye injections with a ...

For the tiniest patients in the neonatal intensive care unit, even a procedure that lasts only minutes can set off a cascade ...

The first patients have been enrolled in 4SIGHT, a global phase 3 trial comparing a single intravitreal injection of the investigational gene therapy 4D-150 with aflibercept 2 mg ...

A blind spot in modern ophthalmology may finally have a name. In a sweeping review published in the Journal of Translational ...